Treatment of Neuromyelitis Optica: Review and Recommendations. - Wikidata - wikimedia - TriplyDB

Treatment of Neuromyelitis Optica: Review and Recommendations.

Treatment of Neuromyelitis Optica: Review and Recommendations.

http://www.wikidata.org/entity/Q37588037

about

An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica International consensus diagnostic criteria for neuromyelitis optica spectrum disorders Challenges and opportunities in designing clinical trials for neuromyelitis optica Neuroinflammation: Ways in Which the Immune System Affects the Brain Treatment of neuromyelitis optica: state-of-the-art and emerging therapies Neuromyelitis optica: clinical features, immunopathogenesis and treatment.Neuromyelitis optica spectrum disorders associated with other autoimmune diseases.Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later.Systemic Lupus Erythematosus (SLE) Complicated by Neuromyelitis Optica (NMO - Devic's Disease): Clinic-Pathological Report and Review of the Literature.Recurrent Longitudinally Extensive Myelitis and Aquaporin-4 Seronegativity - The Expanding Spectrum of Neuromyelitis Optica.Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging.Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders.A Rare Case of Neuromyelitis Optica Spectrum Disorder in Patient with Sjogren's Syndrome.Rituximab as a first-line preventive treatment in pediatric NMOSDs: Preliminary results in 5 children.Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).Development of an Aquaporin-4 Orthogonal Array of Particle-Based ELISA for Neuromyelitis Optica Autoantibodies Detection.Autoimmune thyroiditis associated with neuromyelitis optica (NMO)Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders Bevacizumab is safe in acute relapses of neuromyelitis optica.Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange.Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic.The ethics of placebo controlled clinical trials in NMO - A balance of risks Placebo-controlled study in neuromyelitis optica-Ethical and design considerations Early indicators of relapses vs pseudorelapses in neuromyelitis optica spectrum disorder.Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder.The Prevalence of Anti-Aquaporin 4 Antibody in Patients with Idiopathic Inflammatory Demyelinating Diseases Presented to a Tertiary Hospital in Malaysia: Presentation and Prognosis.Longitudinally extensive myelopathy in children.Multiple sclerosis and pregnancy in the 'treatment era'.Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses.Neuromyelitis optica and pregnancy.Neuromyelitis Optica (Devic's Syndrome): an Appraisal.What's new in neuromyelitis optica? A short review for the clinical neurologist.Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study.Efficiency of antibody therapy in demyelinating diseases.What Is the Optimal Sequence of Rescue Treatments for Attacks of Neuromyelitis Optica Spectrum Disorder?The impact of 2015 neuromyelitis optica spectrum disorders criteria on diagnostic rates.Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability.Cortical blindness and not optic neuritis as a cause of vision loss in a Sjögren's syndrome (SS) patient with the neuromyelitis optica spectrum disorder (NMOSD): Challenges of ascribing demyelinating syndromes to SS: a case report Secondary progression and innate immunity in NMO: A possible link to alemtuzumab therapy?Circulating microRNAs as biomarkers for rituximab therapy, in neuromyelitis optica (NMO).

P2860

Q26748601-2603E60C-08D2-4F69-927A-7867822C0774 Q26824579-01F5AB50-8D74-4A83-9300-8D05E61FB8DE Q26999708-4D759AB2-4C8C-483F-8E42-55AE8F522582 Q28080620-07689915-BABF-49A8-9527-96962C4D7BF5 Q28245749-6D3A2052-48B9-466A-9731-6202A2ACFDF3 Q30785267-CB4F8C67-B48E-4DDE-ADD5-CDD8ECAAECA6 Q30832651-D08A77DD-8A78-477A-B2D3-C802A3FF1FFB Q30975717-9FC68CDB-E1A5-4107-959F-87C0D5129CE7 Q33734731-FBCC0F2D-7B49-403D-B857-1153444E75A7 Q33741772-DC717E8A-DA8A-457E-B100-502A2D3F422C Q34486834-DCBF7BED-8DB4-4479-B601-4A0FDD036FF7 Q34545836-4A3E1DBE-E0E8-42A0-ACB9-B948FA6F2B23 Q34620768-E15FC102-E8C9-4B16-BA47-FCA302AE8083 Q34714525-84783D7A-CBDE-47A3-A1A7-274D42A8B620 Q35052199-E89D8CEA-96F1-4358-BBA4-4A2260E3E65E Q35850484-F7C52D84-B66D-4E35-962C-C25AF0B01A14 Q36291868-CEC4A27D-714A-43C4-B404-F79294D35F6D Q36484394-ADCC7E82-03D9-4F99-852A-F039637E6907 Q36510648-EDF48DAF-0ADA-44D0-BD7B-EE1302A5399A Q36696590-07E4B9A5-1271-4F7D-AAFF-ED904B7D8399 Q36727762-AED6A043-0027-41F9-ADE5-4E1066AA993F Q36736121-24A14182-5E8F-426B-8052-A42D68DF999F Q36996492-8774BFE0-A505-49DA-8705-7A5B32CA7B90 Q37137834-B44C13A1-CBCF-45A2-A33C-4F921FE17D81 Q37365089-61F50983-1277-47BE-A060-ECCA112D41C5 Q37620245-563973F2-EEA9-4C9C-8623-4BC521E2BD47 Q38338052-BAFEB08B-7C06-4051-9660-0336F3143AD6 Q38431744-97691101-6AE9-48B7-887C-3AC6F7FA2722 Q38625492-1530999E-DF06-4624-B951-041A4837ADCD Q38866313-D76D566B-E291-4A4D-A7A0-9F278EC44159 Q38893206-9E4AEEA5-89B2-4679-A8D8-BE60B0F3D5F9 Q39176987-2FF4FFF0-E35D-4B15-9487-6467C099F104 Q39692977-021CAC6B-6715-4172-B9E6-00D25948E578 Q40045794-D4B71A90-6099-4577-90BE-9CEE084C7477 Q40314562-3CF1FD1B-A6A0-42F0-AA69-4B14E13AFBE5 Q40565668-3EE9DF89-5515-4A90-A408-6C2032119D5D Q40715894-8533A31F-FA8F-4EF5-A052-800D954B91AD Q41523649-A6AA67D5-FF56-4CEF-B67F-7C90CBC024DB Q41958613-3F03D212-A46B-4CBC-953E-46D1F8BC3644 Q42427048-240883E7-1E84-4669-A5DA-B63F699C9272

P2860

Treatment of Neuromyelitis Optica: Review and Recommendations.

http://www.wikidata.org/entity/Q37588037

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on October 2012

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Treatment of Neuromyelitis Optica: Review and Recommendations.

@en

Treatment of Neuromyelitis Optica: Review and Recommendations.

@nl

type

label

Treatment of Neuromyelitis Optica: Review and Recommendations.

@en

Treatment of Neuromyelitis Optica: Review and Recommendations.

@nl

prefLabel

Treatment of Neuromyelitis Optica: Review and Recommendations.

@en

Treatment of Neuromyelitis Optica: Review and Recommendations.

@nl

P1433

Q37588037-17BB0622-B248-4B12-9A04-100071D7C0E7

P1476

Q37588037-AB74297C-A304-4502-A1D6-896B1023D3F5

P2093

Q37588037-01DBBBD1-D7E3-4872-9948-F37E339854D5

Q37588037-214F9438-58DC-4AE7-9E6B-7BE94A085880

Q37588037-2CAFEA9B-5D3F-4252-A924-9886FD3E0005

Q37588037-522CD4CC-C4CD-440A-808C-D34D1FED0EF2

Q37588037-5DDA7B8E-8192-4FC1-98AB-15941F330566

Q37588037-61EF8307-8301-4DF7-884F-32A23C725291

Q37588037-8B6D7476-F8DA-4D70-81C4-6BB3CAE7EC40

Q37588037-8C897D55-30FF-452F-82EA-BF1AE3579638

Q37588037-AA1688FA-D79A-40D4-8B90-3E2150E93466

Q37588037-D15EC454-15CA-436B-8F75-547F4EA347EC

P2860

Q37588037-0B552EC6-8215-48EE-840F-2EE986618EAA

Q37588037-108685A9-0AD2-4CC9-A748-405809D8F25D

Q37588037-12DEFE9B-992B-4E92-B1C9-B72569C5B0F8

Q37588037-27F45846-2E07-4AFF-AE7F-EDAD03864E31

Q37588037-2925CFEB-F6F4-4B47-BBC5-9355A6E1D47D

Q37588037-2CFB87D2-12BC-4437-A98C-E2DFD1C5EB94

Q37588037-32638624-D065-4CE9-B88A-161B7163A302

Q37588037-39015FBA-4310-4D11-BFAB-FB2E8454E7A4

Q37588037-4270AABA-34C6-45C1-B3B7-DB7C6E3DF0C8

Q37588037-4E496202-EFCD-48D2-97EF-3BB7C4314193

P304

Q37588037-25761B2B-7823-49B1-9632-13CE061A8F76

P31

Q37588037-707B2573-D536-4FE2-9A05-20E2A18E5F13

P356

Q37588037-DD3AB348-9C2E-43C5-B382-F9EF9D5B5F93

P433

Q37588037-9F8354B0-E46C-483B-86DA-49E0DC2AF319

P478

Q37588037-C64DE6C2-9288-400B-81F3-2A8260A29317

P50

Q37588037-8C8DC254-D641-4538-AC74-6F0F413EC871

Q37588037-C0983A78-0956-4E8B-9A7E-17E6C4CF6A63

Q37588037-D611B44A-F14C-467C-A062-0353521BFA37

P577

Q37588037-2175F4FC-C029-4DDF-A0B3-DF9B40F6F8FF

P5875

Q37588037-ABC2BF15-99AC-4E5F-B211-602138242A1E

P698

Q37588037-FECCC552-8F54-4F56-ACD5-1723070CECC0

P932

Q37588037-82FEF7D6-D188-47BF-AAC4-8FEE5C6F9D17

P356

J.MSARD.2012.06.002

P1433

Multiple Sclerosis and Related Disorders

P1476

Treatment of Neuromyelitis Optica: Review and Recommendations

@en

P2093

Anu Jacob

http://www.w3.org/2001/XMLSchema#string

Brian G Weinshenker

http://www.w3.org/2001/XMLSchema#string

Dean M Wingerchuk

http://www.w3.org/2001/XMLSchema#string

Emmanuelle Waubant

http://www.w3.org/2001/XMLSchema#string

GJCF-CC&BR

http://www.w3.org/2001/XMLSchema#string

Jacqueline Palace

http://www.w3.org/2001/XMLSchema#string

Jérôme de Seze

http://www.w3.org/2001/XMLSchema#string

Kazuo Fujihara

http://www.w3.org/2001/XMLSchema#string

Marco A Lana-Peixoto

http://www.w3.org/2001/XMLSchema#string

Maria Isabel Leite

http://www.w3.org/2001/XMLSchema#string

P2860

IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel

Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity

Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

CNS aquaporin-4 autoimmunity in children.

Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.

Neuromyelitis optica treatment: analysis of 36 patients.

A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica.

A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.

Revised diagnostic criteria for neuromyelitis optica.

P304

180-187

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.MSARD.2012.06.002

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P50

Ichiro Nakashima

Anthony Traboulsee

P577

2012-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262046605

http://www.w3.org/2001/XMLSchema#string

P698

24555176

http://www.w3.org/2001/XMLSchema#string

P932

3926208

http://www.w3.org/2001/XMLSchema#string